AAPG Ascentage Pharma Group International Final Profit

Corporate emblem and logo of Ascentage Pharma (AAPG)

Ascentage Pharma Group is strengthening its status as an innovator in global oncology by developing breakthrough treatments. The company's gross profit, for which this chart from the GURU.Markets terminal confirms the current trend, is recorded at -0.21. However, clinical trial uncertainty and fierce competition create significant risks. A chronic revenue deficit and depleting reserves force the business to constantly seek external financing.

AAPG (Ascentage Pharma Group) Net Profit history from 01/25/2025 to 10/30/2026

Analytical breakdowns and data insights for company Ascentage Pharma (AAPG)

- stock value and consensus price forecast:
Market Price Ascentage Pharma Corp|AAPG - Price Target Chart
- market capitalization data:
Market Value Ascentage Pharma Corp|AAPG - Real Price to Acquire Entire Company
- business book valuation details:
Accounting Value of a Share Ascentage Pharma|AAPG - Book Capitalization|Market Cap to Net Assets Ratio ascentage.com|AAPG - Cumulative Company Assets
- debt and solvency information:
Total Debt to Capital Ascentage Pharma Group|AAPG - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Ascentage Pharma Group International|AAPG - Company Aggregate Debts|Debts to Book Value Ascentage Pharma Corp|AAPG - Company Long-Term Debts|Company Short-Term Debts Ascentage Pharma|Interim Coverage Ratio ascentage.com
- net income and valuation multiples indicators:
AAPG - Net Profit
Fundamental valuation:AAPG Ascentage Pharma Corp
Manufactured product of Ascentage Pharma Group International

Scaling oncology drug sales in Asia creates operational leverage for Ascentage Pharma Group (AAPG), which is reflected in the company's net economic effect as the relative impact of R&D costs decreases. Daily calculation of this metric allows investors to filter out speculative noise from fundamental growth, warning against the risk of purchasing an overvalued asset during unjustified local profit peaks.

Direct competitors

Company Net Income BeiGene Oncology (ONC)|Company Net Income Halozyme Therapeutics|RVMD: Final Profit|Net Income CGON (CG Oncology)|URGN (UroGen Pharma Ltd) - Final Profit|Net Profit BCAX (Bicara Bio)|PSNL - Net Income|ERAS: Net Income|DCTH - Net Profit|Y-mAbs Therapeutics, Inc. (YMAB) - Company Net Income|Aura Biosciences Inc - Final Profit|CADL (Candel Therapeutics Inc.) - Net Profit|Company Net Income Accuray, Inc. ARAY|Net Profit SLS|Net Profit actuatetherapeutics.com (ACTU)|Company Net Income Citius Oncology CTOR|Net Financial Result TuHURA Biosciences Inc. (HURA)|Protara - Net Profit|Fate Pharma (FATE) - Net Income|WHWK: Net Profit|Company Net Income TScan Therapeutics, Inc. (TCRX)|Company Net Income Champions Oncology Inc|Company Profit XBIT (XBiotech USA)|Net Income CVM (CEL-SCI Corporation)|Profit After Payment of Taxes OSTX|Net Profit RADX (Radiopharm Theranostics Limited)|Net Profit Artiva Biotherapeutics Inc. ARTV|Adlai Nortye Limited - Net Profit|Annual Net Income Veru Inc (VERU)|TPST: Net Profit|Company Net Income Xilio Therapeutics (XLO)|Net Income RENB|MURA: Final Profit|Company Net Income Kairos Pharma Ltd (KAPA)|OKUR: Profit After Tax|Net Profit GDTC (CytoMed Therapeutics Limited)|Final Profit CRIS|Apollomics Corp - Net Profit|THAR - Net Profit|advanbiomed.com (ADVB) - Company Net Income|Genprex Inc. - Final Profit|Company Net Income Calidi Biotherapeutics Inc.|Net Income Sunshine Biopharma Inc. (SBFM)|Net Profit XBIO|Net Profit salariuspharma.com (SLRX)|Purple Biotech Ltd. - Net Income|Final Profit AONC|BeOne Medicines - Net Profit|Annual Net Income Checkpoint Therapeutics Inc (CKPT)|Elevation Oncology, Inc. (ELEV) - Company Net Income|iCAD - Final Profit|Company Net Income Ikena Oncology Inc.|Company Net Income Notable Labs Ltd NTBL|Net Income VIRX (Viracta Therapeutics)|Net Profit MorphoSys Corporation (MOR)|Company Net Income NAYA Biosciences NAYA|AAPGV (ascentage.com) - Profit After Tax